Patients' knowledge and perceived understanding – Associations with consenting to participate in cancer clinical trials  by Brandberg, Yvonne et al.
lable at ScienceDirect
Contemporary Clinical Trials Communications 2 (2016) 6e11Contents lists avaiContemporary Clinical Trials Communications
journal homepage: www.elsevier .com/locate/conctcPatients' knowledge and perceived understanding e Associations with
consenting to participate in cancer clinical trials
Yvonne Brandberg a, Hemming Johansson a, b, Mia Bergenmar a, c, *
a Department of Oncology-Pathology, Karolinska Institutet Z1:00, Karolinska University Hospital, SE-17176 Stockholm, Sweden
b Department of Oncology, Karolinska University Hospital, SE-17176 Stockholm, Sweden
c Center for Digestive Diseases, Karolinska University Hospital, SE-141 86 Stockholm, Swedena r t i c l e i n f o
Article history:
Received 31 August 2015
Received in revised form
5 November 2015
Accepted 7 December 2015
Available online 17 December 2015
Keywords:
Cancer clinical trial
Informed consent
Knowledge
Understanding
Recruitment
Quality of informed consent* Corresponding author. Department of Digestive D
Hospital, Huddinge K53, SE-141 86 Stockholm, Swede
E-mail addresses: yvonne.brandberg@ki.se (
johansson@karolinska.se (H. Johansson), mia.bergenm
http://dx.doi.org/10.1016/j.conctc.2015.12.001
2451-8654/© 2015 The Authors. Published by Elseviera b s t r a c t
Recruitment to clinical trials is essential. The aims of the study were to investigate associations between
patients' informed consent to participate in a cancer clinical trial and knowledge and perceived un-
derstanding of the trial. Furthermore, associations between demographic factors and consent to
participate and knowledge and perceived understanding of information about the trial were studied.
Methods: The patients were recruited in connection to a visit at the oncology clinic for information about
a drug trial. The Quality of Informed Consent questionnaire was mailed to the patients after they had
decided about participation in the trial. The associations of demographic factors and “knowledge” and
“perceived understanding” were analysed using linear regression models.
Results: A total of 125 patients were included. Higher levels of “knowledge” and “understanding” were
found to be associated with consent to participate in a clinical trial, both in the univariate and multi-
variate analyses (p ¼ 0.001). None of the tested demographic factors were related to consent to
participate. No statistically signiﬁcant associations between any of the demographic factors and
knowledge or perceived understanding scores were found.
Conclusion: The results indicate that interventions that increase patients' knowledge and perceived
understanding might improve participation rates in clinical trials.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinical trials are of outmost importance in order to ﬁnd new
treatments and improve the existing ones. Low accrual rates may
have several clinical, scientiﬁc, economic and ethical adverse ef-
fects [1e3]. In addition, low recruitment rates might harm the
detection of clinically relevant differences, increasing the risk of
abandoning an effective intervention. This leads to delay of
implementation of new more effective treatments. Furthermore,
investigations of novel research questions and the identiﬁcation of
non-effective interventions might be delayed. Clinical trials are
costly to conduct, both in terms of human resources and ﬁnancially.
It is therefore important to reach conclusive results as soon as
possible.iseases, Karolinska University
n.
Y. Brandberg), hemming.
ar@ki.se (M. Bergenmar).
Inc. This is an open access article uIn order to increase participation in clinical trials, knowledge
about factors included in the recruitment process is of importance,
i.e. factors related to the protocol, the patient or the physician. Such
factors have been investigated in a number of studies [4e9]. One
study showed that travel time and physician communication were
associated with participation in clinical trials [4]. Another study
found concerns about the trial setting, disliking randomization,
discomfort with the research process, the study protocol, potential
side-effects of participating and the patients' perception of the
physician's attitudes towards the trial to be important [5]. Reduced
decisional conﬂict was found to be associated with trial participa-
tion by Miller and co-workers [7]. Altruism has also been identiﬁed
as a factor of importance [6]. In addition, physician related factors
have been found to be associated with participation [6,9]. One
study showed, for example, that the major reason for non-inclusion
in clinical trials was the physician's failure to inform about the trial
[9]. Furthermore, socioeconomic and clinical factors might inﬂu-
ence participation. In a recent study, low level of education, non-
metastatic disease, no previous clinical trial participation and
ﬁnancial burdenwere reported as barriers for trial participation [8].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion, that the patient has knowledge and perceive that he/she un-
derstands all relevant aspects of the trial. Despite these
requirements, many studies show insufﬁcient knowledge and un-
derstanding among patients participating in clinical trials [10e13].
Trial participants may hold signiﬁcant misunderstandings,
although reporting being well informed [12e14]. A number of
studies have been conducted aiming at improving patients'
knowledge and understanding in association to the informed
consent procedure [3,15,16].
Although there are a number of studies on associations between
patients' knowledge and understanding on participation in clinical
trials, it is not known whether better knowledge and understand-
ing are related to participation in clinical trials. A possible scenario
might be that better knowledge and understanding are associated
with lower participation rates, thus constituting a conﬂict between
the interest of improving patients' knowledge and understanding
at the time for informed consent, and the pursuit of increasing
participation rates in clinical trials.
The aims of the present study were ﬁrstly to investigate asso-
ciations between consenting to participate in a cancer clinical trial
and knowledge and perceived understanding of information about
the clinical trial. Secondly, we aimed to evaluate the associations
between demographic factors and 1) consenting to participate in a
cancer clinical trial and 2) knowledge and perceived understanding
of information about the clinical trial.
The Regional Ethical Review Board at Karolinska Institutet
approved the study (2005/604-31/3).
2. Methods
2.1. Patients and procedure
Patients in the present paper were recruited for a randomised
study of an audio-recorded intervention aiming at improving pa-
tients' knowledge and understanding in the informed consent
procedure. The study, which has been presented elsewhere,
showed no effects of the audio-recorded intervention [17].
The patients planned for information about a cancer clinical trial
in phases 2 or 3 between 2008 and 2013. They were included in the
intervention study by a study nurse in connection with a visit for
information about the drug trial. No other inclusion or exclusion
criteria besides those applied in the clinical drug trials were used in
the study. The questionnaires were mailed to the patients together
with prepaid envelopes when they had decided about participation
in the clinical trial. Data on participation in the clinical trial (signed
informed consent form) or not was collected from the trial data-
base. One reminder was sent to those who did not respond within
two weeks. Clinical data were collected from patients' ﬁles.
2.2. The instrument
The questionnaire Quality of Informed Consent (QuIC) was used,
consisting of two parts [18]. The ﬁrst part, “knowledge” includes 20
items, out of which 14 are trial phase independent. The responses
are given in three categories (“disagree”, “unsure”, “agree”). The
second part, “perceived understanding”, consists of 14 items where
patients rate to what extent they perceived that they understood
the information about the clinical trial. The response format is a 5-
point scale from “I didn't understand this at all” to “I understood
this very well”. The English version of the QuIC has been validated
[18]. QuIC was translated to Swedish by a forward-backward pro-
cedure followed by pilot testing in accordance with the guidelines
by the European Organization for Research and Treatment of Can-
cer (EORTC) Quality of Life Group [19], and has been usedpreviously [20]. For patients declining participation in the drug
trial, the wording was changed to “the trial you were informed
about and asked to consider” instead of “your clinical trial”, as
stated in the original questionnaire.
2.3. Statistical methods
The two randomized groups in the intervention study were well
balanced with respect to demographic variables [17]. Thus, the data
from the two groups were compiled in the present analyses.
The ﬁrst part of the questionnaire QuIC, “knowledge”, was
scored in the following way. Responses categorized as “correct”
were assigned the value of 100. Incorrect responses and responses
in the category “unsure” were assigned the value of 0. The phase
independent questions only were included in the analyses of
“knowledge”. In the second part, “perceived understanding”, the
response format is a 5-point scale from “I didn't understand this at
all” to “I understood this very well”. Correspondingly, the responses
were assigned the values 0, 25, 50, 75 and 100. For both parts
(knowledge/perceived understanding) respectively, the scores
were summated and divided by the number of items.
The following variables were included in the multivariate lo-
gistic and linear regressions for “knowledge” and “perceived un-
derstanding”: age, gender, education, “cohabitant status”,
“randomized study or not”. The two parts were not included in the
same multivariate logistic regressions, but were tested separately
as they are intended to assess different features. The effects of
different factors on “knowledge” and “perceived understanding”
were tested and estimated using linear regression models. Results
from these analyses are presented as mean differences and 95%
conﬁdence intervals. The odds of consenting to participate in a
cancer trial were modelled using unconditional logistic regression.
The results from these models are presented as odds-ratios. All
reported p-values are two-sided and based on the Wald-test. The
level of statistical signiﬁcance was set to 0.001 to correct for
multiple testing.
3. Results
3.1. Patient characteristics
A total of 183 patients were invited to participate in the audio-
recording study, 53 (29%) declined, leaving 130 (71%) patients in
the study. Out of those, 5 patients were included in the intervention
study, but were not asked to participate in a drug trial (“too ill”¼ 3,
“language problems” n ¼ 1, “administrative failure” n ¼ 1). Thus,
125 patients were included in the present analyses. In all, 16 drug
trials were represented, out of which 14 were randomized (10
Phase 3 trials). A total of 13 oncologists performed the inclusion in
the drug trials. As presented elsewhere, the patients showed rela-
tively high levels of knowledge and understanding [17]. Patients'
demographic and clinical characteristics are presented in Table 1.
The majority was between 45 and 64 years of age, well educated,
co-habitants and the majority (82%) were women.
3.2. Associations between consenting to participate in a drug trial
and knowledge, perceived understanding of information about the
clinical trial and demographic factors
Table 2 presents the results of the univariate and multivariate
analyses of associations between consenting to participate in a drug
trial and demographic factors and the knowledge and under-
standing scores. Higher “knowledge” was associated with con-
senting to participate in a drug trial in both the univariate and
multivariate analyses (p ¼ 0.001). In addition, a similar result was
Table 1
Patients demographic and clinical characteristics.
Characteristic N ¼ 125
Age N (%)
<45 20 (16)
45e64 85 (68)
65 20 (16)
Mean [SD] 55 [10.6]
Gender
Females 103 (82)
Males 22 (18)
Education
Compulsory school (1e9 years) 18 (14)
Senior high school (10e12 years) 20 (16)
University education (13e16 years) 14 (11)
Higher university education (16 years) 48 (39)
Data missing 25 (20)
Marital status
Married/living with partner 70 (56)
Living alone 30 (24)
Missing 25 (20)
Diagnosis
Breast 98 (78)
Gastro-intestinal 18 (14)
Prostate 9 (8)
Participation in the clinical drug trial
Yes 91 (73)
No 34 (27)
Study phase
Phase III 75 (60)
Phase II (randomized) 25 (20)
Phase II (single-arm) 25 (20)
Table 2
Consent to participate in clinical trials: Uni- and multivariate analyses of associations with demographic factors, knowledge and perceived understanding.
Univariate analysis Multivariate analysis knowledgea Multivariate analysis
understandinga
Factor Participating (%)/Not
participating
Odds ratio (95% conﬁdence
interval)
P Odds ratio (95% conﬁdence
interval)
P Odds ratio (95% conﬁdence
interval)
P
Age
<45 17 (85)/3 Reference Reference Reference
45e64 60 (71)/25 0.42 (0.11e1.58) 0.41 (0.07e2.42) 0.34 (0.06e2.11)
65 14 (70)/6 0.41 (0.09e1.95) 0.26d 1.87 (0.11e32.6) 0.67d 2.37 (0.11e49.8) 0.58d
Gender
Male 17 (77)/5 Reference Reference Reference
Female 74 (72)/29 0.75 (0.25e2.22) 0.60 0.46 (0.07e3.08) 0.43 0.26 (0.02e2.92) 0.28
Educationb
Elementary school 15 (83)/3 Reference Reference Reference
High school 15 (75)/5 0.60 (0.12e2.97) 0.47 (0.07e3.9) 0.73 (0.10e5.26)
University 51 (82)/11 0.93 (0.23e3.76) 0.92d 1.03 (0.20e5.31) 0.97d 1.89 (0.32e11.2)- 0.97d
Living alone or notb
Cohabitant 58 (83)/12 Reference Reference Reference
Alone 23 (77)/7 0.68 (0.24e1.94) 0.47 1.15 (0.33e3.94) 0.83 0.65 (0.18e2.38) 0.52
Randomized study or not
Not randomized 19 (76)/6 Reference Reference Reference
Randomized 72 (72)/28 0.81 (0.29e2.24) 0.69 1.49 (0.39e5.72) 0.56 1.44 (0.33e6.28) 0.63
Knowledge score,c mean
[SD]
72 [15.1] 1.39e (1.15e1.65) <0.001 1.39e (1.14e1.69] 0.001 e
Understanding score,b
mean [SD]
86 [12.4] 1.43e (1.16e1.77) 0.001 e 1.54e (1.20e1.97) 0.001
Total 91 (73)/34
P-values in bold indicates statistical signiﬁcance.
a Adjusted for all other listed factors.
b Data missing for 25 patients.
c Data missing for 24 patients.
d Test for linear trend.
e OR corresponding to an increase in knowledge score with 5 units.
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was predictive of consenting (p ¼ 0.001). None of the other tested
demographic factors appeared to be related to consent to partici-
pate in a drug trial. In conclusion, the results indicate that higherknowledge and better understanding are associated with con-
senting to participate in a clinical trial.3.3. Associations between knowledge score/perceived
understanding score and demographic factors
We found no statistically signiﬁcant associations between any of
the demographic factors and knowledge or perceived under-
standing scores, Tables 3 and 4. Thus, these variables do not seem to
be related to knowledge about clinical trials and perceived
understanding.4. Discussion
The present study aimed at identifying factors of importance for
consenting to participate in cancer clinical trials. A number of de-
mographic variables, as well as “knowledge” and “perceived un-
derstanding” of the speciﬁc trial the participant was asked to
consider, were entered into the analyses. Higher knowledge and
understanding were found to be associated with consent to
participate, even after accounting for other factors. None of the
demographic factors were, however, related to consenting. In
addition, the association between the demographic factors and
knowledge and understanding were investigated, but no associa-
tions were found.
“Knowledge” and “perceived understanding”were assessed by a
questionnaire developed based on the requirements of informedconsent in cancer clinical trials [18]. This is a brief, valid and reliable
instrument, and the Swedish translation has been validated [20].
The “knowledge” part can be considered to objectively measure
knowledge about the drug trial that the patient is considering to
Table 3
Univariate and multivariate analyses of associations between “Knowledge”z and demographic factors.
Univariate analysis Multivariate analysisa
Factor N [%] Mean
(SD)
Mean difference (95% conﬁdence
interval)
P Mean difference (95% conﬁdence
interval)
P
Age
<45 18
[18]
75 (14.7) Reference Reference
45e64 68
[67]
72 (14.6) 3 (10 to 5) 0.67 2 (10 to 6) 0.86
65 15
[15]
70 (16.0) 5 (15 to 5) 0.38# 3 (14 to 8) 0.60#
Gender
Male 17
[17]
72 (13.7) Reference Reference
Female 84
[83]
73 (15.0) 1 (7 to 8) 0.88 1 (9 to 8) 0.89
Education
Elementary school 18
[18]
69 (14.5) Reference Reference
High school 20
[20]
76 (17.4) 7 (3 to 16) 0.37 6 (4 to 16) 0.50
University 62
[61]
73 (13.5) 4 (4 to 11) 0.37# 3 (5 to 12) 0.46#
Missing 1 [1] e e e
Living alone or not
Cohabitant 70
[69]
74 (12.7) Reference Reference
Alone 30
[30]
70 (17.9) 4 (11 to 2) 0.17 4 (11 to 2) 0.19
Missing 1 [1] e e e
Randomized study or not
Not randomized 22
[22]
77 (16.8) Reference Reference
Randomized 79
[78]
71 (14.0) 6 (13 to 2) 0.12 6 (13 to 1.3) 0.11
Total number of patients in the study with information on
knowledge
101 72 (14.7)
z Part A. Phase speciﬁc questions excluded. Total number of questions included 14 (out of 20). For each question, correct answers are assigned a score of 100, unsure and
incorrect answers are assigned a score of 0.# Test for linear trend. a Adjusted for all other listed factors. a Adjusted for all listed factors.
Linear regression was used to estimate mean differences and conﬁdence intervals. All reported p-values are two-sided and based on the Wald test.
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response alternative. Thus, they are less prone to subjective re-
sponses, although there is of course a risk of choosing the right
answer by chance. It is encouraging that higher levels of knowledge
relate to willingness to consent, thus educational efforts for pa-
tients in connection to inclusion in clinical trials might result in a
higher proportion of patients consenting to participate. The ﬁnding
that perceived understanding was related to consent indicates that
the patients also perceived themselves as well informed. It must be
considered, however, that the patients responded to the ques-
tionnaire after the decision to participate or not in a drug trial.
Therefore, there is a risk of response bias in that those who con-
sented might have been more prone to express that they under-
stood the information about the trial than those who declined.
Knowledge, on the other hand, was not likely to be affected by
response bias, as the questions are based on facts about participa-
tion in a clinical trial. Previous studies, have however, not found
associations between knowledge and participation in clinical trials,
using QuIC [4,10]. There were no associations between “knowl-
edge” and educational level in that study, also including a high
proportion of well-educated participants.
Physicians' recommendation to patients to participate in a
clinical trial increases the likelihood that the patient will take the
decision to participate [5,21]. Baseline levels of knowledge could
also have contributed to the decision to participate or not, but these
were not assessed in the present study. Baseline attitudes toward
participation in clinical trials could also have contributed to theassociation found between consent to participate in a clinical trial
and knowledge and understanding [8]. Those who had negative
attitudes to participation in clinical trials at the medical consulta-
tion might have been less prone to listen to the information and
consequently reported lower levels of knowledge and perceived
understanding, and decided thereafter not to participate in the
clinical trial they were informed about. In addition, those who
consented might have been more interested to read and learn more
about the trial than those who did not.
Thirteen physicians were involved in including patients in drug
trials in this study. Thus, it is unlikely that the skills of an individual
physician account for the results. It has earlier been recognised that
information in connection to inclusion in clinical trials is a difﬁcult
and time-consuming task [22,23]. Probably, the physicians involved
in our study varied with respect to information skills.
The present study investigates the associations between
selected factors related to consent to participate in clinical trials,
such as age, gender, education, marital status and whether the drug
trial was a randomized study or not, as well as knowledge and
understanding. In addition to our results, other studies have found
a number of other factors of importance for participation in clinical
trials not investigated in the present study [4,6,8,9,24]. These have
also to be considered in the informed consent procedure.
We choose to assign 100 point to a correct response to each item
in the knowledge questionnaire in the present study, but unlike
most other authors, assign 0 for both the incorrect alternative and
the “unsure” option [14,18]. The reason was the requirement of
Table 4
Univariate and multivariate analyses of associations between “Perceived understanding”a and demographic factors.
Univariate analysis Multivariate analysisc
Factor N [%] Mean
(SD)
Mean difference (95% conﬁdence
interval)
P Mean difference (95% conﬁdence
interval)
P
Age
<45 18
[18]
85 (12.5) Reference Reference
45e64 67
[67]
86 (12.4) 1 (5 to 8) 0.58 0 (7 to 7) 0.73
65 15
[15]
83 (12.4) 2 (11 to 6) 0.60b 3 (12 to 6) 0.51b
Gender
Male 16
[16]
85 (10.4) Reference Reference
Female 84
[84]
86 (12.7) 1 (6 to 7) 0.91 1 (9 to 6) 0.74
Education
Elementary school 18
[18]
87 (12.1) Reference Reference
High school 19
[19]
90 (8.7) 3 (5 to 11) 0.20 3 (5 to 12) 0.23
University 62
[62]
84 (13.0) 3 (9 to 4) 0.36b 2 (9 to 5) 0.51b
Missing 1 [1] e e e
Living alone or not
Cohabitant 70
[70]
84 (12.2) Reference Reference
Alone 29
[29]
89 (11.6) 5 (0e10) 0.062 5 (1 to 10) 0.084
Missing 1 [1] e e e
Randomized study or not
Not randomized 21
[21]
89 (11.0) Reference Reference
Randomized 79
[79]
85 (12.6) 4 (10 to 2) 0.24 3 (9 to 3) 0.32
Total number of patients in the study with information on
knowledge
100 86 (12.4)
Linear regression was used to estimate mean differences and conﬁdence intervals. All reported p-values are two-sided and based on the Wald test.
a Part B. Total number of questions included 13 (out of 14). Answer to questions are coded 1,2,3,4,5 and are assigned scores of 0, 25, 50, 75 and 100.
b Test for linear trend.
c Adjusted for all other listed factors.
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dividuals who participate in clinical trials should be fully knowl-
edgeable regarding the clinical trial and about the implication of
participation. Therefore, we did not consider the “unsure” option to
fulﬁl the requirements of informed consent. Correct responses only
were regarded as indicative of actual knowledge. The fact that we
have applied this method of scoring makes it difﬁcult to compare
the levels of knowledge in our study with other studies using the
QuIC. Other studies have assigned the value of 50 to the “unsure”
response alternative, probably resulting in higher levels of knowl-
edge reported from those studies. We have, however, used this
method in our previous studies, where similar high levels of
knowledge were found [17,20].
The high proportion of well educated participants in our study
indicates a selection of patients asked to participate in clinical trials
in general, not representative of the Swedish general population. A
further support for the lack of representativeness of patients asked
to participate in drug trials is the ﬁnding in our previous study [20].
In that study, including all patients (n ¼ 282) who consented to
participate in clinical trials during 1 year at the Department of
Oncology, Karolinska University Hospital, we found a high pro-
portion of well-educated patients. Almost half of them reported
having a university education. Trialists running these studies
should therefore address the selection of patients for inclusion in
clinical trials as to also include less educated patients, as this is a
matter of equality.The results of a positive association between participation in
clinical trials and knowledge and perceived understanding are
promising, as there was a risk of ﬁnding a negative association.
Such a ﬁnding would imply a conﬂict between the requirements of
informed consent and the pursuit of increasing participation rates
in clinical trials. Our results, however, indicate that striving for
increasing knowledge and understanding, fulﬁlling the re-
quirements of the Helsinki Declaration, can be performed hand in
hand with efforts to improve participation rates in these trials.
The study has some limitations. The sample size is relatively
small. In addition, breast cancer studies were overrepresented,
making the gender balance skewed. The scoring of “knowledge”
used in our study differs from the scoring suggested by the original
authors [18]. In the original paper, the authors state that the reason
for assigning the “unsure” option 50 is “because we preferred that
subjects recognize areas of uncertainty, rather than be certain of
false beliefs”. We consider our scoring method, where correct re-
sponses only were regarded as indicative of actual knowledge, to be
more accurate according to the criteria of the Helsinki Declaration.
The patient should be knowledgeable of all relevant aspects of the
trial, and the QuIC is developed based on these requirements. Thus,
in the ideal situation, all patients consenting to participate in a trial
should respond correctly to all items in the knowledge part of the
QuIC.
The study also has some strengths. Most studies of factors of
importance for participation in cancer clinical trials have used
Y. Brandberg et al. / Contemporary Clinical Trials Communications 2 (2016) 6e11 11attitudes toward participation as an outcome, whereas the
outcome in the present study was actual taking the decision
whether to sign informed consent or not. Other strengths include
the use of a validated questionnaire, and that as many as 13 on-
cologists and 16 trials were represented. In addition, the response
rate to the questionnaire was high.
5. Conclusion
In summary, higher knowledge and perceived understanding
were related with consenting to participate in clinical trials. No
association between demographic factors were found, neither to
consenting, nor to knowledge or understanding. Our results indi-
cate that interventions aiming at increasing knowledge and
perceived understanding might improve participation rates in
clinical trials.
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